Search the KHIT Blog

Friday, November 6, 2020

US Covid19 new cases explosion

224,719 new US cases on Nov 4th and 5th combined. Two consecutive days above 100,000.

Hopkins graphic, US daily new cases:

On Oct 1st Hopkins reported 44,771 new cases.

I dropped some of these data into Excel and rendered a quick plot.

Current US death toll as of this posting is more than 235,000.


My latest Science Magazine came today.

As if there were any doubt that U.S. President Donald Trump has no respect for scientists, he now refers to public health scholars as “Fauci and all these idiots.” That's how he's describing experts in virology, immunology, epidemiology, and infectious disease. Never mind that after recovering from coronavirus disease 2019 (COVID-19), Trump suddenly became excited about future vaccines and “Regeneron,” which is what he calls monoclonal antibodies in general. (Regeneron Pharmaceuticals, Inc. is probably thrilled to have achieved the product-brand status of Xerox and Kleenex, but Eli Lilly also has developed promising monoclonals, and more are in clinical trials.) Apparently, no one told the president that scientists from these same fields—many of whom live in “Democrat-run cities” or college towns and are immigrants who wouldn't be here under his policies—created these drugs and carried out the decades of science that made them possible. This paradox of loving the drug but hating the science is nothing new. It's just louder this time…

A recent survey from the Pew Research Center found that only 20% of the political right has “a lot” of confidence in scientists. Yet when folks at this end of the political spectrum get sick, they want the best treatments that secular academic medicine can provide. The consequences of this are profound and especially apparent in the COVID-19 crisis. The same politicians who are criticizing public health guidance are praising vaccines and antibodies without acknowledging that they come from the same principles and researchers as masks and social distancing…

H. Holden Thorp, Editor in Chief


No comments:

Post a Comment